Literature DB >> 32908827

When the Treatment is the Cause: Disseminated Bacille Calmette-Guérin Infection.

Ana Teresa Marques Afonso1, Montserrat Rodríguez Framil1, Joaquín Sánchez Leira1, Néstor Vázquez Agra1, Federico García-Rodeja Arias2.   

Abstract

Bacille Calmette-Guérin (BCG) administration for superficial bladder cancer is a well-tolerated and very effective therapy. However, unpredictable systemic complications may occur on rare occasions. We present the case of a patient who attended for consultation because of fever, asthenia and weight loss following BCG immunotherapy. The clinical response to treatment and computed tomography scanning were key to diagnosis. LEARNING POINTS: It is essential to keep a high index of suspicion of possible, although uncommon, complications in patients treated with BCG immunotherapy.Response to treatment should always be evaluated to confirm diagnostic suspicion. © EFIM 2020.

Entities:  

Keywords:  BCG infection; hepatitis; miliary tuberculosis

Year:  2020        PMID: 32908827      PMCID: PMC7473691          DOI: 10.12890/2020_001697

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  6 in total

1.  Detection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma.

Authors:  Argyrios Siatelis; Dimitra P Houhoula; Joseph Papaparaskevas; Dimitrios Delakas; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

Review 2.  Complications of intravesical therapy for urothelial cancer of the bladder.

Authors:  Madhusudan P Koya; Michael A Simon; Mark S Soloway
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

3.  History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.

Authors:  Harry W Herr; Alvaro Morales
Journal:  J Urol       Date:  2007-11-13       Impact factor: 7.450

4.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

Review 5.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

6.  Miliary Tuberculosis that Developed after Intravesical Bacillus Calmette-Guerin Therapy.

Authors:  Kyohei Kaburaki; Keishi Sugino; Muneyuki Sekiya; Yujiro Takai; Kazutoshi Shibuya; Sakae Homma
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.